Pegylated Interferon-α2b plus Ribavirin: An Efficacious and well-Tolerated Treatment Regimen for Patients with Hepatitis C virus Related Histologically Proven Cirrhosis
Luigi Roff(Azienda Ospedaliera di Valtellina e Valchiavenna), Savino Bruno(Humanitas University), Pierpaolo Parravicini(Azienda Socio Sanitaria Territoriale della Valtellina e Alto Lario), Chiara Corradi(University of Pisa), Roberto Ceriani(Paoli Hospital), Valentina Bellia, Pietro Pioltelli(University of Milan), Giovanni Fornaciari, P. Del Poggio, Angelo Rossini(Centro Universitário Barão de Mauá), G Ramella, Guido Colloredo(King's College Hospital), Massimo Pozzi(Azienda Ospedaliera San Gerardo), G. Bellati(Fondazione Ricerca Molinette)
Cited by 33
Related Papers
International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways
|Nature Communications|2015|312
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication
|Journal of Hepatology|2016|273
Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group
|Journal of Hepatology|2022|172
Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C†
|Hepatology|2005|166
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
|Journal of Hepatology|2018|133